Shermila Pia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shermila Pia has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- David Looi
Neurology, California Northstate University College of Medicine, Elk Grove, USA
1 shared publication - Forshing Lui
Office of Research, College of Medicine, California Northstate University, Elk Grove, California 95757, United States of America
1 shared publication - Ning Zhong
Neurology, Kaiser Permanente Sacramento Medical Center, Sacramento, USA
1 shared publication - Robert Thompson Stone
Department of Neurology, Golisano Children's Hospital, University of Rochester, Rochester, New York, United States
1 shared publication
Latest Publications
- Open Access
- 27 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33047
An Unusual Case of Two Paraneoplastic Neurological Syndromes in a Patient With Lung Cancer
Paraneoplastic immune-mediated disorders have been well described in the literature. However, it is still relatively rare. The incidence has increased over the past decade due largely to the discovery of more autoantibodies. With a better understanding of the pathophysiology of different autoantibodies and clinical phenotypes, we are often able to diagnose clinically some specific paraneoplastic autoimmune neurological syndromes. We may also predict the response to treatment based on the autoantibody class. We are presenting a very unusual case of two completely different paraneoplastic syndromes with two different autoantibodies, gamma-aminobutyric acid-B (GABAB) and collapsin response mediator protein 5 (CRMP5), in a patient with underlying small-cell lung cancer. We will discuss the differences in the two antibody syndromes, their significance, and their management.
- 27 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33047
Open AccessAn Unusual Case of Two Paraneoplastic Neurological Syndromes in a Patient With Lung Cancer
Paraneoplastic immune-mediated disorders have been well described in the literature. However, it is still relatively rare. The incidence has increased over the past decade due largely to the discovery of more autoantibodies. With a better understanding of the pathophysiology of different autoantibodies and clinical phenotypes, we are often able to diagnose clinically some specific paraneoplastic autoimmune neurological syndromes. We may also predict the response to treatment based on the autoantibody class. We are presenting a very unusual case of two completely different paraneoplastic syndromes with two different autoantibodies, gamma-aminobutyric acid-B (GABAB) and collapsin response mediator protein 5 (CRMP5), in a patient with underlying small-cell lung cancer. We will discuss the differences in the two antibody syndromes, their significance, and their management.